Munich Cancer Registry

- Incidence and Mortality
- Selection Matrix
- Homepage
- *Deutsch*

ICD-10 C88,C90: Immunoprolif. disease

Survival

Year of diagnosis	1988-1997	1998-2014
Patients	461	3,882
Diseases	461	3,886
Cases evaluated	403	2,428
Creation date	03/02/2016	
Export date	12/23/2015	
Population	4.64 m	

Munich Cancer Registry at Munich Cancer Center
Marchioninistr. 15
Munich, 81377
Germany

http://www.tumorregister-muenchen.de/en

http://www.tumorregister-muenchen.de/en/facts/surv/sC8890E-ICD-10-C88-C90-Immunoprolif.-disease-survival.pdf



Figure 1a. Relative survival of patients with immunoprolif. disease by period of diagnosis. Included in the evaluation are 2,790 cases diagnosed between 1988 and 2014.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 1998 to 2011, and are represented by gray diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided population-based statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

	Period of diagnosis					
	1988-1997 n=401		1998-2006 n=1,073		2007+ n=1,316	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0
1	87.9	90.0	79.8	81.9	79.6	81.9
2	74.4	78.0	65.7	69.1	67.9	71.6
3	62.9	67.5	57.7	62.1	57.7	62.4
4	54.7	60.1	50.0	55.1	49.8	55.1
5	48.0	53.8	42.0	47.4	41.3	46.8
6	41.5	47.7	35.5	40.9	36.2	42.1
7	36.6	42.8	31.7	37.4	33.3	39.4
8	32.9	39.5	27.2	32.8		
9	30.1	36.6	23.8	29.2		
10	27.0	33.7	20.0	25.3		

Table 1b. Observed (obs.) and relative (rel.) survival of patients with immunoprolif. disease by period of diagnosis for period 1988-2014 (N=2,790).



Figure 2a. Survival of patients with immunoprolif. disease by gender. Included in the evaluation are 2,790 cases diagnosed between 1988 and 2014.

	Gender			
	Male n=1,531		Female n=1,259	
Years	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0
1	82.1	84.6	79.3	81.3
2	69.8	73.9	65.8	68.9
3	60.7	65.8	55.8	59.7
4	52.5	58.5	48.3	52.8
5	44.7	50.9	40.4	45.1
6	38.3	44.8	34.6	39.4
7	35.4	42.5	29.7	34.5
8	31.0	38.1	25.5	30.1
9	27.9	35.1	22.2	26.7
10	23.7	30.7	19.7	24.0

Table 2b. Observed (obs.) and relative (rel.) survival of patients with immunoprolif. disease by gender for period 1988-2014 (N=2,790).



Figure 2c. Conditional relative 2 / 5-year survival of patients with immunoprolif. disease by gender. For 2,790 of 2,790 cases diagnosed between 1988 and 2014 valid data could be obtained for this item.

	Gender					
	Male			Female		
		Cond. surv. %			Cond. surv. %	
Years	n	2 yrs	5 yrs	n	2 yrs	5 yrs
0	1,531	73.9	50.9	1,259	68.9	45.1
1	1,219	77.9	53.1	974	73.6	48.6
2	984	79.3	57.8	773	76.8	50.4
3	801	77.5	58.3	611	75.7	50.9
4	637	76.9	60.6	487	75.0	51.2
5	496	83.8	60.9	381	76.9	53.9
6	389	85.7	62.9	294	77.0	56.4
7	311	83.2	59.7	225	78.0	56.1
8	240	80.9	60.4	166	80.1	55.9
9	190	79.4	62.7	128	82.2	58.3
10	148	82.0	70.1	99	79.5	59.0

Table 2d. Conditional relative 2 / 5-year survival of patients with immunoprolif. disease by gender for period 1988-2014 (N=2,790).

Conditional relative survival rates refer to the relative survival probability, in this case for 2 and 5 years after cancer diagnosis, compared to the age- and sex-matched population (=100%) under the condition of being alive for a certain time period (x-axis in Figure 2a). The results illustrate to what extent the cancer induced mortality of particular subgroups declines in the subsequent years after detection of the malignancy. For instance, according to the presented survival statistics, patients in the subgroup gender="Male", who are alive at least 3 years after cancer diagnosis, the conditional relative 2-year survival rate is 77.5% (n=801).



Figure 3a. Relative survival of patients with immunoprolif. disease by age category. Included in the evaluation are 2,790 cases diagnosed between 1988 and 2014.

	Age category									
	0-49 yrs n=254		50-59 yrs n=467		60-69 yrs n=851		70-79 yrs n=863		80+ yrs n=355	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	95.2	95.1	90.9	91.3	86.4	87.5	76.4	78.9	55.3	60.5
2	88.0	88.2	81.8	82.7	74.6	76.8	61.5	65.9	35.4	42.6
3	82.6	82.8	75.1	76.5	65.2	68.1	49.8	55.5	24.5	32.8
4	77.9	78.7	70.7	72.5	56.2	59.7	39.6	46.0	18.1	26.8
5	70.6	71.3	62.2	64.4	47.6	51.6	31.9	38.8	12.0	20.1
6	63.7	64.6	55.2	57.8	41.6	46.0	25.4	32.6	7.7	15.0
7	63.0	63.7	50.1	52.8	36.4	41.1	21.4	29.0	6.8	15.0
8	58.8	59.5	47.0	50.1	30.7	35.3	16.5	23.7		
9	53.9	55.0	42.8	45.9	26.5	31.3	14.5	22.0		
10	49.5	50.3	37.3	40.5	24.0	29.0	9.6	15.7		

Table 3b. Observed (obs.) and relative (rel.) survival of patients with immunoprolif. disease by age category for period 1988-2014 (N=2,790).



Figure 5a. Time to first progression of 2,370 patients with immunoprolif. disease diagnosed between 1998 and 2014 (M0 only in solid cancers) estimated by cumulative incidence function (CI, solid line) accounting for death as competing risk and by inverse Kaplan-Meier estimate (1-KM, dashed line). The frequency of events may be underestimated due to underreporting.

	Type of progression	
	Any type (CI) n=2,370	Any type (1-KM) n=2,370
Years	%	%
0	0.0	0.0
1	28.1	29.1
2	42.7	45.1
3	52.6	56.5
4	58.3	63.5
5	62.9	69.5
6	65.2	72.5
7	67.2	75.3
8	68.5	77.3
9	69.3	78.8
10	70.2	80.3

Table 5b. Time to first progression of patients with immunoprolif. disease for period 1998-2014 (N=2,370).



Figure 5c. Observed post-progression survival of 963 patients with immunoprolif. disease diagnosed between 1998 and 2014. These 963 patients with documented progression events during their course of disease represent 40.6 % of the totally 2,373 evaluated cases. Patients with cancer relapse documented via death certificates only were excluded (n=513, 21.6 %).

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement “not specified” is the only information in registries regarding relapse of the disease. The category “Any type” denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100% value because patients are potientially considered in more than one subgroup.

	Type of progression
	Any type n=963
Years	%
0	100.0
1	68.4
2	51.9
3	40.5
4	32.7
5	27.3
6	23.2
7	20.1
8	15.6
9	12.3
10	9.8

Table 5d. Observed post-progression survival of patients with immunoprolif. disease for period 1998-2014 (N=963).



Figure 5e. Observed post-progression (any type) survival of 1,209 patients with immunoprolif. disease diagnosed between 1988 and 2014 by period of progression.

	Period of progression		
	1988-1997 n=141	1998-2006 n=459	2007+ n=609
Years	%	%	%
0	100.0	100.0	100.0
1	60.9	67.8	68.9
2	47.6	51.6	52.9
3	36.4	42.7	39.1
4	27.5	36.0	30.7
5	21.6	30.5	26.6
6	15.5	25.7	22.2
7	14.0	21.8	20.9
8	13.2	17.4	
9	11.6	14.7	
10		12.8	

Table 5f. Observed post-progression (any type) survival of patients with immunoprolif. disease for period 1988-2014 by period of progression (N=1,209).

Shortcuts

MCR	Munich Cancer Registry, Germany	
NCI	National Cancer Institute, USA	
SEER	Surveillance, Epidemiology, and End Results, USA	
UICC	Union for International Cancer Control, Geneva	
DCO	Death certificate only	Death certificate provides the only notification to the registry.
NA	Not available	
NOS	Not otherwise specified	
OS	Overall/Observed survival	Overall/Observed survival (Kaplan-Meier estimate) Date of entry: diagnosis Event: death from any cause
RS	Relative survival	Survival compared to “general population”, ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival
AS	Assembled survival	Assembled chart of observed, expected, relative survival
CS	Conditional survival	Survival probability under the condition of surviving a given period of time
TTP	Time to progression	Time to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression
	1-KM	1 minus Kaplan-Meier estimator (“inverse” Kaplan-Meier estimator)
	CI	Cumulative incidence Death as competing risk (according to Kalbfleisch und Prentice)
PPS	Post-progression survival	Survival since first progression / relapse (Kaplan-Meier estimate) Date of entry (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression Event: death from any cause

Recommended Citation

Munich Cancer Registry. Survival ICD-10 C88,C90: Immunoprolif. disease [Internet]. 2016 [updated 2016 Mar 2; cited 2016 May 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/surv/sC8890E-ICD-10-C88-C90-Immunoprolif.-disease-survival.pdf

Copyright

Disclaimer

Index of figures and tables